Against long odds, conventional wisdom and politics, efforts to commercialize stem cell research are underway and show signs of intelligent life. Stephan Herrera investigates.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Related links
Related links
Related links in Nature Research
Licensing fees slow advance of stem cells
Korean team lauded for stem-cell advance
Stem-cell therapies: The first wave
Web links
Rights and permissions
About this article
Cite this article
Herrera, S. Leaders and laggards in the stem cell enterprise. Nat Biotechnol 23, 775–777 (2005). https://doi.org/10.1038/nbt0705-775
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0705-775
This article is cited by
-
Canada’s Stem Cell Corporation: Aggregate Concerns and the Question of Public Trust
Journal of Business Ethics (2007)
-
Erratum: Leaders and laggards in the stem cell enterprise
Nature Biotechnology (2005)
